A real-world study in Galicia showed nirsevimab reduced RSV-related hospitalizations by 85.9% in the first season and 55.3% in the second. The RSV prevention market is expanding to cover high-risk children, with Beyfortus the only antibody approved for second-season use. The FDA has cited Sanofi for misleading promotional claims about the product.
Merck's Enflonsia (clesrovimab) receives EU approval for RSV prevention in infants. Separately, researchers identify a monoclonal antibody cocktail from pediatricians' immune cells that shows potent protection against RSV and hMPV in animal studies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07774494 |
Effect of AI-Assisted Discharge Education on Parents of Children With Bronchitis/Bronchiolitis |
NOT_YET_RECRUITING | NA |
| NCT07631377 |
The LalelaLung Study: Digital Stethoscope Clinical Evaluation |
NOT_YET_RECRUITING | PHASE4 |
| NCT06932341 |
Evaluation of the Impact of EHR-Alerts on Clinical Decision Support Pathway Use in Bronchiolitis, and the Impact of Pathway Use on the Prescription of High Flow Nasal Cannula and Other Elements of High Value Care. |
COMPLETED | NA |
| NCT06842238 |
Descriptive Study of the Initial Management of Young Children With Moderate Acute BRONCHiotitis With Home Hospitalisation |
TERMINATED | |
| NCT06016244 |
Safe, Effective and Cost-Effective Oxygen Saturation Targets for Children and Adolescents With Respiratory Distress: a Randomized Controlled Trial |
COMPLETED | NA |
| NCT05909566 |
Respiratory Support and Treatment for Efficient and Cost-Effective Care |
ACTIVE_NOT_RECRUITING | NA |
| NCT03298217 |
Peak Tidal Inspiratory Flow in Infants With Moderate to Severe Acute Viral Bronchiolitis |
COMPLETED | NA |
| NCT02824744 |
Comparison Between 2l vs 3l in HFNC During the Initial Management of Severe Bronchiolitis in Infants |
COMPLETED | NA |
